Total Funding
41
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
152867
Ralexar Therapeutics focuses on the development of an innovative portfolio of liver X receptor agonists.
Dave Pfeiffer: President & CEOPast Role: Nitric Bio, Chief Operating Officer- Kamil Ali-Jackson: Co-founder, Chief Legal Officer and SecretaryPast Role: Aclaris Therapeutics, Co-Founder and Retired Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
About the Company
Ralexar Therapeutics company is developing topical and systemic therapies based on the Liver X Receptor (LXR) modulators. The initial focus for the company is on the clinical development of ALX-101, a topical LXR-based therapy, for the treatment of various cutaneous inflammatory disorders, including atopic dermatitis.
Alexar changes its name to
Ralexar Therapeutics. The company was founded in 2013 and is based in Malvern, Pennsylvania.
